DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect m...

Full description

Saved in:
Bibliographic Details
Published inAnnals of clinical and translational neurology Vol. 8; no. 8; pp. 1738 - 1744
Main Authors Sormani, Maria Pia, Salvetti, Marco, Labauge, Pierre, Schiavetti, Irene, Zephir, Helene, Carmisciano, Luca, Bensa, Caroline, De Rossi, Nicola, Pelletier, Jean, Cordioli, Cinzia, Vukusic, Sandra, Moiola, Lucia, Kerschen, Philippe, Radaelli, Marta, Théaudin, Marie, Immovilli, Paolo, Casez, Olivier, Capobianco, Marco, Ciron, Jonathan, Trojano, Maria, Stankoff, Bruno, Créange, Alain, Tedeschi, Gioacchino, Clavelou, Pierre, Comi, Giancarlo, Thouvenot, Eric, Battaglia, Mario Alberto, Moreau, Thibault, Patti, Francesco, De Sèze, Jérôme, Louapre, Celine
Format Journal Article
LanguageEnglish
Published Bognor Regis John Wiley & Sons, Inc 01.08.2021
Wiley
John Wiley and Sons Inc
Subjects
Age
Brief Communication
Brief Communications
Coronaviruses
COVID-19
Females
Hospitalization
Life Sciences
Meta-analysis
Multiple sclerosis
Neurons and Cognition
Pandemics
Severe acute respiratory syndrome coronavirus 2
Standard deviation
Systematic review
Ventilators
France
Italy
Online AccessGet full text

Cover

More Information
Summary:We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect meta‐analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti‐CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid‐19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled‐analysis confirms an increased risk of severe Covid‐19 in patients on anti‐CD20 therapies and supports the protective role of interferon.
Bibliography:This study received no specific funding. French Clinical Research Infrastructure Network for Multiple Sclerosis (FCRIN4MS) is supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" program, and by the ARSEP Foundation. Paris Brain Institute (ICM) Clinical Research Infrastructure Network (iCRIN) is supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche", within the framework of the “Institut Hospitalo‐Universitaire” program. The Observatoire Français de la Sclérose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" program, under the reference ANR‐10‐COHO‐002, by the Eugène Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation.
The members of the group authors are included in a supplemental file.
Funding Information
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC8351392
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.51408